- Home
- NBIX vs BAX Comparison
NBIX vs BAX Comparison
Compare NBIX & BAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIX
- BAX
- Stock Information
- Founded
- NBIX 1992
- BAX 1931
- Country
- NBIX United States
- BAX United States
- Employees
- NBIX N/A
- BAX N/A
- Industry
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- BAX Medical/Dental Instruments
- Sector
- NBIX Health Care
- BAX Health Care
- Exchange
- NBIX Nasdaq
- BAX Nasdaq
- Market Cap
- NBIX 14.4B
- BAX 11.3B
- IPO Year
- NBIX 1996
- BAX N/A
- Fundamental
- Price
- NBIX $154.77
- BAX $17.87
- Analyst Decision
- NBIX Strong Buy
- BAX Hold
- Analyst Count
- NBIX 18
- BAX 10
- Target Price
- NBIX $172.06
- BAX $27.00
- AVG Volume (30 Days)
- NBIX 1.0M
- BAX 7.6M
- Earning Date
- NBIX 10-28-2025
- BAX 10-30-2025
- Dividend Yield
- NBIX N/A
- BAX 3.79%
- EPS Growth
- NBIX 12.44
- BAX N/A
- EPS
- NBIX 4.19
- BAX N/A
- Revenue
- NBIX $2,682,700,000.00
- BAX $11,023,000,000.00
- Revenue This Year
- NBIX $23.68
- BAX $5.72
- Revenue Next Year
- NBIX $18.02
- BAX $2.52
- P/E Ratio
- NBIX $36.93
- BAX N/A
- Revenue Growth
- NBIX 19.61
- BAX 3.90
- 52 Week Low
- NBIX $84.23
- BAX $17.47
- 52 Week High
- NBIX $157.67
- BAX $37.74
- Technical
- Relative Strength Index (RSI)
- NBIX 67.44
- BAX 19.23
- Support Level
- NBIX $133.62
- BAX $17.47
- Resistance Level
- NBIX $157.67
- BAX $23.35
- Average True Range (ATR)
- NBIX 4.47
- BAX 0.57
- MACD
- NBIX 1.07
- BAX -0.50
- Stochastic Oscillator
- NBIX 87.92
- BAX 6.52
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About BAX Baxter International Inc.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.